Freenome, a biotechnology company focused on early cancer detection through blood tests, laid off approximately 20% of its workforce in early 2024, affecting around 100 employees. The reduction was part of a strategic restructuring to extend its financial runway and prioritize key clinical and operational goals amid a challenging funding environment for the life sciences sector. The company, which employs about 500 people, aims to streamline operations while advancing its multi-cancer screening programs.
